Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: segal e. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
Venkatanarayan A, Liang J, Yen I, Shanahan F, Haley B, Phu L, Verschueren E, Hinkle TB, Kan D, Segal E, Long JE, Lima T, Liau NPD, Sudhamsu J, Li J, Klijn C, Piskol R, Junttila MR, Shaw AS, Merchant M, Chang MT, Kirkpatrick DS, Malek S. Venkatanarayan A, et al. Among authors: segal e. Cell Rep. 2022 Feb 8;38(6):110351. doi: 10.1016/j.celrep.2022.110351. Cell Rep. 2022. PMID: 35139374 Free article.
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, Kharbanda S, Raisner R, Haverty PM, Modrusan Z, Ly J, Choo E, Kaufman S, Beresini MH, Romero FA, Magnuson S, Gascoigne KE. Jin L, et al. Among authors: segal e. Cancer Res. 2017 Oct 15;77(20):5564-5575. doi: 10.1158/0008-5472.CAN-17-0314. Epub 2017 Aug 17. Cancer Res. 2017. PMID: 28819026
IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment.
Harnoss JM, Le Thomas A, Reichelt M, Guttman O, Wu TD, Marsters SA, Shemorry A, Lawrence DA, Kan D, Segal E, Merchant M, Totpal K, Crocker LM, Mesh K, Dohse M, Solon M, Modrusan Z, Rudolph J, Koeppen H, Walter P, Ashkenazi A. Harnoss JM, et al. Among authors: segal e. Cancer Res. 2020 Jun 1;80(11):2368-2379. doi: 10.1158/0008-5472.CAN-19-3108. Epub 2020 Apr 7. Cancer Res. 2020. PMID: 32265225 Free PMC article.
Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A. Harnoss JM, et al. Among authors: segal e. Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429. doi: 10.1073/pnas.1906999116. Epub 2019 Aug 1. Proc Natl Acad Sci U S A. 2019. PMID: 31371506 Free PMC article.
803 results